About: Evaluation of the adverse effects of oral firocoxib in healthy dogs

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the adverse effects of oral firocoxib in healthy dogs Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the adverse effects of oral firocoxib in healthy dogs
Creator	Ferreira, T Vinicius, Paulo Luna, F Luna, S Mantovani, F Moutinho, F Salcedo, E Steagall, Mortensen Steagall, P
Source	Medline; PMC
abstract	This study evaluated the adverse effects of oral firocoxib in dogs. Six dogs (20.2 ± 6.3 kg) were studied. Values for complete blood count (CBC), serum urea, creatinine, alanine transaminase, alanine phosphatase, γ‐glutamyl transferase, occult blood in feces, platelet aggregation, and buccal mucosal bleeding time were measured before and 7, 14, 21, and 29 days after SID treatment with firocoxib 5.3 ± 0.34 mg/kg (FG) or lactose 1 mg/kg (LG) for 28 days, in a randomized crossover study. Gastrointestinal (GI) tract endoscopy was performed before treatment began and at 29 days. Lesions were scored from grade 0 to 6. Data were analyzed using anova and paired t‐tests (P < 0.05). None of the dogs presented adverse clinical effects. There were no significant changes in CBC, biochemical profiles within groups, or differences between groups. Pretreatment mean ± SD bleeding time (LG, 70.7 ± 32.1 sec; FG, 75.8 ± 38.1 sec) and platelet aggregation (LG, 86.4 ± 10.2%; FG, 85.6 ± 9.2%) were not significantly different from readings at 29 days (LG, 95.2 ± 25 sec; FG, 91.7 ± 24 sec and LG, 73.2 ± 15.1%; FG, 84 ± 10.3%) nor the groups were different. None of the dogs had positive fecal occult blood tests, and endoscopic lesion scores were grade 0 both before treatment and at 29 days. Administration of firocoxib did not cause any adverse effects on GI, or hematological or serum biochemical variables and appears to have been well tolerated by dogs.
has issue date	2007-03-27(xsd:dateTime)
bibo:doi	10.1111/j.1365-2885.2007.00842.x
bibo:pmid	17472653
has license	no-cc
sha1sum (hex)	5f41a2f57f2f1961ee1db956a4367a8df8d16c36
schema:url	https://doi.org/10.1111/j.1365-2885.2007.00842.x
resource representing a document's title	Evaluation of the adverse effects of oral firocoxib in healthy dogs
has PubMed Central identifier	PMC7194286
has PubMed identifier	17472653
schema:publication	J Vet Pharmacol Ther
resource representing a document's body	covid:5f41a2f57f2f1961ee1db956a4367a8df8d16c36#body_text
is schema:about of	named entity 'creatinine' named entity 'adverse' named entity 'randomized' named entity 'Six' named entity 'alanine' named entity 'transferase' named entity 'variables' named entity 'RANDOMIZED CROSSOVER STUDY' named entity '38.1' named entity 'BEFORE TREATMENT' named entity 'SERUM' named entity 'DIFFERENT' named entity 'CHANGES' named entity 'DAYS' named entity 'POSITIVE' named entity 'EVALUATION' named entity 'FIROCOXIB' covid:arg/5f41a2f57f2f1961ee1db956a4367a8df8d16c36 named entity 'days' named entity 'scored' named entity 'None' named entity 'bleeding time' named entity 'dogs' named entity 'mucosal' named entity 'studied' named entity 'tolerated' named entity 'performed' named entity 'Data' named entity 'bleeding time' named entity 'dogs' named entity 'fecal occult blood' named entity 'CBC' named entity '28 days' named entity 'adverse effects' named entity 'bleeding time' named entity 'endoscopic' named entity 'occult blood' named entity 'firocoxib' named entity 'lactose' named entity 'biochemical' named entity 'complete blood count' named entity 'lesion' named entity 'crossover study' named entity 'CBC' named entity 'ANOVA' named entity 'phosphatase' named entity 'hematological' named entity 'endoscopy' named entity 'creatinine' named entity 'fecal occult blood' named entity 'adverse effects' named entity 'groups' named entity 'Tokyo' named entity 'selective COX-2 inhibitors' named entity 'pyloric antrum' named entity 'rofecoxib' named entity 'anticoagulant' named entity 'Friedman test' named entity 'renal damage' named entity 'drug-related' named entity 'endoscopy' named entity 'ulcers' named entity 'mucosa' named entity 'rofecoxib' named entity 'bleeding time' named entity 'ADP' named entity 'firocoxib' named entity 'mucosa' named entity 'homeostasis' named entity 'bleeding time' named entity 'COX-1' named entity 'COX' named entity 'ad libitum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software